NV-AIRCRAFT-PERFORMANCE
11.10.2021 22:31:10 CEST | Business Wire | Press release
NBAA-BACE – Aircraft Performance Group (APG) announces iPreFlight Genesis™ Pro, a new solution that seamlessly coordinates between aircraft dispatchers and flight crews, enabling optimized global flight planning with integrated enroute, take-off, and landing performance. iPreFlight Genesis Pro is the culmination of APG’s proven track record of 20+ years of providing trusted runway performance for over 350 aircraft profiles and over 9,000 monitored airports combined with RocketRoute’s global routing and filing capabilities and Seattle Avionics’ global ChartData. APG, RocketRoute, and Seattle Avionics all recently joined forces under the AFV Partners LLC umbrella.
iPreFlight Genesis Pro provides optimized and fully integrated tools for both dispatchers and flight crews. Dispatchers have access to a comprehensive and flexible web-based application for global routing, runway performance, weight and balance, and flight plan calculation and filing. Flight crews can use the iPad application to review and modify trip plans at any point during the mission, verify runway performance calculations, and check weight and balance parameters. Routes and flight plans are fully synchronized between the web and iPad applications enabling seamless bi-directional collaboration between pilots and dispatchers, eliminating inefficient phone calls, significantly decreasing operational change reaction times, and improving communication accuracy.
“Flight preparation boils down to one important question: What is the most safe, compliant, efficient, and timely manner to get to my destination based on optimized routing considering my aircraft's performance capabilities?” said Shawn Mechelke, president of the Aviation Group at AFV Partners. “APG’s runway performance system is the industry leader in business aviation. Now, with global route optimization and flight plan filing from RocketRoute and global charts from Seattle Avionics, iPreFlight Genesis Pro brings together the many data, calculations, and performance considerations into a seamless interface that is powerful, easy to use, and integrated in both mobile and web applications – no matter where in the world a mission takes you.”
“iPreFlight Genesis Pro uniquely combines the assets and IP of all three companies within our Aviation Group to optimize the flight route based on multiple parameters such as type of aircraft, load factor, weather conditions, and many more data points to deliver a high return on investment solution with a meaningful sustainability impact due to an optimized fuel burn profile for our customers,” said Tony Aquila, founder, chairman, and CEO of AFV Partners. “This solution is the first of many that will leverage the people, technology, and data across APG, RocketRoute, and Seattle Avionics to create new products that will have a lasting positive impact on aviation and the environment.”
KEY BENEFITS
- Realtime responsiveness delivers a superior experience to clients
- Simplifies dispatcher and crew workflow
- Lowers training costs
- Reduces unplanned downtime
- Lowers operating costs and total cost of ownership
KEY FEATURES
- Bi-directional synchronization between dispatchers and flight crews
- Integrated runway performance with flight planning
- Global routing and filing
- Weight and Balance
- Global charts for in-flight and pre-flight use
- Supports web platforms and mobile devices
- Application Programming Interfaces (APIs) allow connection to customer applications
About Aircraft Performance Group
Aircraft Performance Group (APG) is a leading global provider of proprietary flight operations software solutions into the aftermarket of the aerospace industry. APG operates a SaaS business model focused on the corporate and business aviation segment of the aerospace industry. www.flyapg.com
About RocketRoute
RocketRoute is a leading software platform simplifying route planning and flight plan submissions to air traffic controllers. RocketRoute solutions span private, business and commercial aviation, and are the backbone to many air rescue operations in Europe. www.rocketroute.com
About Seattle Avionics
Seattle Avionics creates compelling pre-flight and in-flight user experiences with its cloud-based solutions providing direct user access to flight planning, weather, fuel prices and group document management for the general aviation market. Their ChartData brand of global FAA-certified and georeferenced charts and data is proven and used in leading in-panel avionics systems around the world. www.seattleavionics.com
About AFV Partners
Founded by serial technology entrepreneur and investor Tony Aquila and anchored by some of the world’s largest and most experienced investors, AFV Partners is a long-term sustainable capital vehicle that invests globally in mission critical software, data and disruptive marketplaces that contribute to a net positive impact on the environment. AFV Partners is headquartered in Argyle, TX with offices in Jackson Hole, WY and Zurich, Switzerland. www.afvpartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005683/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom